Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 263.0
(0.23%)
SEK 263.0
(0.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.16 Billion SEK | 54.63% |
| 2022 | 25.97 Billion SEK | 2.02% |
| 2021 | 25.45 Billion SEK | -9.33% |
| 2020 | 28.07 Billion SEK | -2.27% |
| 2019 | 28.72 Billion SEK | 252.79% |
| 2018 | 8.14 Billion SEK | 93.77% |
| 2017 | 4.2 Billion SEK | -9.04% |
| 2016 | 4.61 Billion SEK | 27.57% |
| 2015 | 3.62 Billion SEK | 95.98% |
| 2014 | 1.84 Billion SEK | 5.59% |
| 2013 | 1.75 Billion SEK | 18.21% |
| 2012 | 1.48 Billion SEK | -14.73% |
| 2011 | 1.73 Billion SEK | -36.34% |
| 2010 | 2.72 Billion SEK | 87.73% |
| 2009 | 1.45 Billion SEK | 12.28% |
| 2008 | 1.29 Billion SEK | 161.24% |
| 2007 | 495.26 Million SEK | -28.83% |
| 2006 | 695.87 Million SEK | -31.81% |
| 2005 | 1.02 Billion SEK | 196.35% |
| 2004 | 344.33 Million SEK | 23.9% |
| 2003 | 277.91 Million SEK | 4.25% |
| 2002 | 266.58 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 35.08 Billion SEK | -4.7% |
| 2024 Q2 | 36.81 Billion SEK | -4.66% |
| 2024 Q1 | 38.61 Billion SEK | -3.84% |
| 2023 Q4 | 40.16 Billion SEK | -2.38% |
| 2023 Q1 | 26.08 Billion SEK | 0.43% |
| 2023 Q3 | 41.13 Billion SEK | -13.23% |
| 2023 FY | 40.16 Billion SEK | 54.63% |
| 2023 Q2 | 47.4 Billion SEK | 81.76% |
| 2022 Q1 | 25.05 Billion SEK | -1.59% |
| 2022 Q3 | 25.86 Billion SEK | 7.32% |
| 2022 Q2 | 24.1 Billion SEK | -3.79% |
| 2022 FY | 25.97 Billion SEK | 2.02% |
| 2022 Q4 | 25.97 Billion SEK | 0.4% |
| 2021 Q1 | 27.32 Billion SEK | -2.67% |
| 2021 Q4 | 25.45 Billion SEK | 1.87% |
| 2021 Q3 | 24.99 Billion SEK | -0.13% |
| 2021 Q2 | 25.02 Billion SEK | -8.43% |
| 2021 FY | 25.45 Billion SEK | -9.33% |
| 2020 FY | 28.07 Billion SEK | -2.27% |
| 2020 Q1 | 27.77 Billion SEK | -3.31% |
| 2020 Q2 | 24.02 Billion SEK | -13.52% |
| 2020 Q3 | 25.35 Billion SEK | 5.54% |
| 2020 Q4 | 28.07 Billion SEK | 10.76% |
| 2019 Q3 | 17.1 Billion SEK | 12.57% |
| 2019 FY | 28.72 Billion SEK | 252.79% |
| 2019 Q1 | 15.49 Billion SEK | 90.25% |
| 2019 Q2 | 15.19 Billion SEK | -1.9% |
| 2019 Q4 | 28.72 Billion SEK | 67.92% |
| 2018 FY | 8.14 Billion SEK | 93.77% |
| 2018 Q3 | 7.76 Billion SEK | 81.77% |
| 2018 Q2 | 4.27 Billion SEK | 2.45% |
| 2018 Q1 | 4.17 Billion SEK | -0.75% |
| 2018 Q4 | 8.14 Billion SEK | 4.84% |
| 2017 Q4 | 4.2 Billion SEK | -11.02% |
| 2017 Q3 | 4.72 Billion SEK | 0.17% |
| 2017 Q2 | 4.71 Billion SEK | -0.53% |
| 2017 Q1 | 4.74 Billion SEK | 2.6% |
| 2017 FY | 4.2 Billion SEK | -9.04% |
| 2016 Q1 | 3.52 Billion SEK | -2.74% |
| 2016 Q2 | 4.34 Billion SEK | 23.34% |
| 2016 Q3 | 4.42 Billion SEK | 1.84% |
| 2016 Q4 | 4.61 Billion SEK | 4.43% |
| 2016 FY | 4.61 Billion SEK | 27.57% |
| 2015 Q2 | 1.87 Billion SEK | -4.28% |
| 2015 FY | 3.62 Billion SEK | 95.98% |
| 2015 Q3 | 2.03 Billion SEK | 8.26% |
| 2015 Q4 | 3.62 Billion SEK | 78.22% |
| 2015 Q1 | 1.96 Billion SEK | 6.12% |
| 2014 Q1 | 1.78 Billion SEK | 1.75% |
| 2014 Q3 | 1.83 Billion SEK | 3.8% |
| 2014 Q4 | 1.84 Billion SEK | 0.55% |
| 2014 FY | 1.84 Billion SEK | 5.59% |
| 2014 Q2 | 1.77 Billion SEK | -0.57% |
| 2013 Q1 | 1.72 Billion SEK | 16.7% |
| 2013 FY | 1.75 Billion SEK | 18.21% |
| 2013 Q4 | 1.75 Billion SEK | 1.1% |
| 2013 Q3 | 1.73 Billion SEK | -1.69% |
| 2013 Q2 | 1.76 Billion SEK | 1.92% |
| 2012 Q1 | 1.68 Billion SEK | -3.17% |
| 2012 Q2 | 1.67 Billion SEK | -0.64% |
| 2012 Q3 | 1.57 Billion SEK | -5.99% |
| 2012 Q4 | 1.48 Billion SEK | -5.73% |
| 2012 FY | 1.48 Billion SEK | -14.73% |
| 2011 FY | 1.73 Billion SEK | -36.34% |
| 2011 Q1 | 2.75 Billion SEK | 1.1% |
| 2011 Q2 | 2.1 Billion SEK | -23.6% |
| 2011 Q3 | 1.99 Billion SEK | -5.24% |
| 2011 Q4 | 1.73 Billion SEK | -13.02% |
| 2010 FY | 2.72 Billion SEK | 87.73% |
| 2010 Q4 | 2.72 Billion SEK | -9.66% |
| 2010 Q3 | 3.01 Billion SEK | 0.88% |
| 2010 Q2 | 2.99 Billion SEK | 3.17% |
| 2010 Q1 | 2.9 Billion SEK | 99.66% |
| 2009 Q4 | 1.45 Billion SEK | 0.0% |
| 2009 FY | 1.45 Billion SEK | 12.28% |
| 2008 FY | 1.29 Billion SEK | 161.24% |
| 2007 FY | 495.26 Million SEK | -28.83% |
| 2006 FY | 695.87 Million SEK | -31.81% |
| 2005 FY | 1.02 Billion SEK | 196.35% |
| 2004 FY | 344.33 Million SEK | 23.9% |
| 2003 FY | 277.91 Million SEK | 4.25% |
| 2002 FY | 266.58 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -365822.551% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -488048.778% |
| BioGaia AB (publ) | 302.84 Million SEK | -13160.909% |
| Enzymatica AB (publ) | 49.3 Million SEK | -81357.142% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -270392.355% |
| Gabather AB (publ) | 6.87 Million SEK | -583790.666% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -125454.93% |
| Moberg Pharma AB (publ) | 24 Million SEK | -167184.542% |
| Nanexa AB (publ) | 36.42 Million SEK | -110147.893% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -102995.959% |
| ODI Pharma AB | 10.05 Million SEK | -399197.094% |
| Orexo AB (publ) | 727.7 Million SEK | -5418.758% |
| Probi AB (publ) | 181.31 Million SEK | -22048.932% |
| Swedencare AB (publ) | 2.31 Billion SEK | -1634.548% |
| Toleranzia AB | 6.9 Million SEK | -581170.806% |
| Vivesto AB | 30.45 Million SEK | -131779.679% |